Their combined experience adds breadth and depth across the areas of drug development, venture capital, research, and clinical care.
Boston, MA (PRWEB) October 08, 2013
Joseph Loscalzo, M.D., Ph.D. and Argeris "Jerry" Karabelas, Ph.D., join the Strategic Advisory Board of Broadview Ventures. Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments to support early stage ventures.
"We are excited to add Dr. Loscalzo and Dr. Karabelas to our Strategic Advisory Board," stated Christopher H. Colecchi, Managing Director. "Their combined experience adds breadth and depth across the areas of drug development, venture capital, research, and clinical care."
A leader in Venture Philanthropy, Broadview seeks creative ways to bring advancements in science to the care of patients by making funding available at critical moments in the development of new technologies. Broadview has an impressive history of funding companies such as Aggamin, CardiAQValve Technologies, miRagen, and about a dozen other emerging technology companies.
Dr. Joseph Loscalzo is the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine, Physician-in-Chief at Brigham and Women’s Hospital, Editor-in-Chief of Circulation, a senior editor of Harrison’s Principles of Internal Medicine, a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health.
Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine.
Dr. Argeris "Jerry" Karabelas is a partner at Care Capital in Princeton, NJ, a life sciences venture capital firm with $500 million under management. Jerry was the founder of the Novartis BioVenture Fund. Previous to that he was CEO of the Novartis healthcare division, worldwide, and the Executive VP and head of Global Pharmaceuticals at SmithKline Beecham. Jerry has been chairman of the board of a number of life science companies including Human Genome Sciences, Vanda Pharmaceuticals, Skye Pharma, NitroMed Pharmaceuticals, and Polyphor Pharmaceuticals. Jerry has a Ph.D. in pharmacokinetics from Mass College of Pharmacy and a B.S. in biochemistry from the University of New Hampshire. He was previously a member of Massachusetts General Hospital’s Scientific Advisory Committee and an advisor to the Singapore government's Bio-One Capital.
Fondation Leducq created Broadview Ventures, Inc., to accelerate the translation of scientific discoveries into clinical benefit in cardiovascular and neurovascular disease through targeted investment to support early stage technology. For inquiries and more information please email: info(at)broadviewventures(dot)org.